|Bid||3.3600 x 1000|
|Ask||3.8600 x 1000|
|Day's Range||3.3400 - 3.4300|
|52 Week Range||2.1500 - 7.8000|
|Beta (3Y Monthly)||2.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
VIVUS, Inc. (VVUS) (“VIVUS”), a biopharmaceutical company, today announced an amendment to its manufacturing and supply agreement with Nordmark Arzneimittel GmbH & Co. KG (“Nordmark”) for PANCREAZE® (pancrelipase) Delayed Release Capsules. The amended agreement covers a ten-year initial term and may be renewed for additional five-year periods, the first at VIVUS’ option and by mutual agreement thereafter. Financial terms of the agreement were not disclosed. “As VIVUS continues its 10-quarter turnaround, ensuring PANCREAZE supply to meet the current and future demand for PANCREAZE at a stable and predictable price was a key step in our strategy, and we are pleased to have achieved this important milestone,” said John Amos, Chief Executive Officer at VIVUS.
If you're interested in VIVUS, Inc. (NASDAQ:VVUS), then you might want to consider its beta (a measure of share price...
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced the launch of an e-medicine platform that will enable patients with a prescription for Qsymia® (phentermine and topiramate extended-release) capsules CIV to purchase the medication online and have their orders delivered directly to their homes. The online ordering platform is another component of the Qsymia Advantage Program, which is designed to improve patient access to Qsymia. “One of the consistent pieces of feedback that we have heard from patients utilizing and physicians prescribing Qsymia has been the high out of pocket cost. Historically, the patient’s out of pocket cost has been in excess of $140 per month for the low strength doses and in excess of $200 per month for the high strength doses. These high out of pocket costs limited patients from initiating therapy or continuing therapy after initiation,” said John Amos, Chief Executive Officer at VIVUS.
On May 22nd, the FDA issued a letter to Vivus (VVUS) claiming that the company had made false or misleading claims and/or representations about the efficacy and risks of Qsymia. Based on observations by the Office of Prescription Drug Promotion (OPDP) of the FDA, it has found that the promotional material on the webpage violated the Federal Food, Drug and Cosmetic Act (FD&C Act) and is requesting that Vivus halt its violations. The OPDP requests that Vivus to submit a written response that the company intends to cease (remedy) the violations by June 7th, 2019, listing all promotional materials that include the cited violations along with a plan on how they discontinue their use.
“Adolescent obesity represents one of the most critical medical and public health issues not only because one out of five teenagers is affected, but also due to the fact that medical treatment options are limited,” said Aaron Kelly, PhD, Associate Professor of Pediatrics, Co-Director of the Center for Pediatric Obesity Medicine at the University of Minnesota, and an investigator on the trial. “Childhood and adolescent obesity is known to impact both physical and psychological health, and increases the risks of adult obesity, type 2 diabetes and lipid disorders,” said Santosh T. Varghese, MD, Chief Medical Officer at VIVUS.
CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc., today announced a.
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic insufficiency (EPI) and erectile dysfunction (ED) solutions, Vivus maintains a development program for pulmonary arterial hypertension (PAH). Existing product Qsymia and recently acquired product Pancreaze are expected to be the main revenue drivers over the next several years.
On a per-share basis, the Campbell, California-based company said it had a loss of 75 cents. The biopharmaceutical company posted revenue of $16.1 million in the period. In the final minutes of trading ...
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., April 30, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Long term investing is the way to go, but that doesn't mean you should hold every stock forever...
CAMPBELL, Calif., April 16, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019.
The product will be marketed in the Russian Federation under the brand name RAZATUS. "The approval of avanafil in the Russian Federation adds to the growing list of territories in which the product is now available for the treatment of ED and demonstrates the high quality capabilities of our Regulatory Affairs team, in close collaboration with our partners Sanofi and Menarini, to obtain drug approvals in multiple jurisdictions," said John Amos, Chief Executive Officer at VIVUS. "Following recent approvals of avanafil in Jordan, Saudi Arabia, Turkey and the United Arab Emirates, approval in the Russian Federation further demonstrates the potential of the product in multiple global markets.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Feb. 26, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed.
CAMPBELL, Calif., Feb. 13, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and.
Although many biotech stocks have been hit hard at the start of 2019 while the general market has rallied, this underperformance in the biotechnology space has presented at least two key benefits for investors looking to invest in the area. First, and perhaps the most obvious, is that being able to enter biotech stocks at a cheaper price -- assuming the companies are not fundamentally broken -- is much better than going in while the stocks are overpriced or in "rally mode". Second, in situations like this, companies' dividend yields go up. What all of this means is that despite the seemingly grim picture for biotech, there are actually several solid biotech dividend stocks to invest in now. The struggle is sifting through all the names and finding which of them are the best dividend stocks to invest in. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 F-Rated Stocks That Could Break Your Portfolio But don't worry, I've done the hard work for you. Below are three of the best biotech dividend stocks to buy now. Source: Shutterstock ### AbbVie (ABBV) AbbVie (NYSE:ABBV) trades at a modest price-to-earnings ratio of 21X, while shares yield 5.45%. Although short-term investors might be concerned that ABBV shares have been on a downtrend since topping in May 2018 at $122, there is still plenty of longer-term potential in ABBV to be hyped about. Much of the downside ABBV experienced occurred after its latest earnings report. AbbVie reported fourth-quarter adjusted profits that grew a solid 28% over last year; at $1.90 a share, the company achieved its guidance for the quarter. But the stock gave up around $10 a share, falling from $88 to around $78, after the report. Investors fretted over the 15% drop in international Humira sales. Biosimilar competition in Europe, which makes up 75% of its international Humira business, was expected. However, generic competition for its flagship drug does not concern ABBV management. It's likely that they're banking on a slew of new product releases in 2019 to offset the aggressive discounting from competitors. In fact, AbbVie is funding five major products for launch indications this year. This should drive revenue higher and lead to double-digit earnings-per-share growth for the company. All of which makes it one of the notable biotech dividend stocks to buy. Source: Everjean via Flickr ### Allergan (AGN) Allergan plc (NYSE:AGN) ended its last rally in October 2018, with AGN shares finally bottoming by the end of last year at around $130. The stock fell again from $160 to a recent price of $144 after reporting Q4 results. Right now, AGN shares will pay you a modest 2.1% dividend. And if the stock rebounds, the total return will be higher. The botox specialist reported $4.08 billion in revenue, down 5.7% from last year. Non-GAAP income fell 15.4% to $1.45 billion. Encouragingly, sales of Botox rose 9.4%, while the Juvederm collection, Lo Loestrin and Vraylar all rose in the double digits. Although these products are a smaller part of total revenue, it is enough for management to forecast revenue of $15 billion - $15.3 billion this year. * 7 Stocks That Won Super Bowl Sunday With management forecasting lighter results for the year, why should investors buy AGN stock for the dividends? The firm has six late-stage clinical programs, plans of one to two new product launches annually and the company has strong margins. It made $5.64 billion in operating cash flow last year. This is more than the $976 million it needs for the dividend. Source: Shutterstock ### Sanofi (SNY) After settling at around $42 at the start of 2019, Sanofi (NASDAQ:SNY) rallied steadily to close at around $43.45 recently. Now, at its 50-day simple moving average, shares have a dividend yield of 4.28%. Sanofi's underperformance is unusual. Other than trading at a slightly higher valuation at a P/E of 22X, the company did not report any negative news. If anything, the collaborations that this biotech firm has with Regeneron Pharmaceuticals (NASDAQ:REGN) should bolster investor confidence. Regeneron's Dupixent is becoming a blockbuster hit for treating Atopic Dermatitis. Alongside its efforts with REGN, SNY is also supplying the active ingredient of avanafil to Vivus (NASDAQ:VVUS). Another promising aspect bolstering the case for SNY stock is that on Jan. 23, the Food and Drug Administration approved the use of Sanofi's Fluzone in young children. When it reports earnings on Feb. 7, the company should not bring up any negative surprises. It should be consistent like Q3's report where the company reported sales growing 6.3% (at constant exchange rates). Its Bioverativ acquisition should continue to contribute meaningfully to sales. Looking ahead, an EMA decision in the first half of this year for its oncology drug Libtayo, plus an FDA action date of Feb. 6 for Cablivi, which treats a rare blood disorder, should keep investor confidence high. As of this writing, Chris Lau held shares of ABBV. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 F-Rated Stocks That Could Break Your Portfolio * 5 Fintech Stocks to Buy As This Mega Trend Gains Steam * 10 Cold Weather Stocks to Heat Up Your Returns Compare Brokers The post 3 Biotech Stocks That Pay Solid Dividends appeared first on InvestorPlace.
Pursuant to Rule 14a‑8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholders may present proper proposals for inclusion in the 2019 Proxy Statement and for consideration at the Company’s 2019 Annual Meeting. To be eligible for inclusion in the 2019 Proxy Statement, a proposal must be received by the Company no later than February 18, 2019 and must otherwise comply with Rule 14a‑8.
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
CAMPBELL, Calif., Jan. 14, 2019 -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that results from a new study evaluating the.
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
CAMPBELL, Calif., Dec. 27, 2018 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
If you want to know who really controls VIVUS, Inc. (NASDAQ:VVUS), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions Read More...
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...